NanoViricides, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2018. The supplied filing is an annual report, not a report for 2017 Q4; it includes year-over-year comparisons with fiscal 2017.
Business context
NanoViricides is a development-stage antiviral drug company with no commercial products or revenue. Its pipeline is preclinical and based on licensed nanomedicine technology. In fiscal 2018, the company prioritized its HerpeCide program, particularly a topical shingles (VZV) candidate; other programs include HSV, influenza, HIV, dengue, and additional viruses.
Financial performance and position
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $4.83 million | $5.53 million |
| General and administrative expense | $4.50 million | $4.07 million |
| Total operating expenses / operating loss | $9.33 million | $9.60 million |
| Net loss | $8.56 million | $10.30 million |
| Basic and diluted loss per share | $0.13 | $0.17 |
| Cash used in operating activities | $7.78 million | $7.90 million |
| Cash and cash equivalents at year-end | $7.08 million | $15.10 million |
| Working capital | $6.44 million | $10.62 million |
| Total assets | $18.55 million | $27.00 million |
| Total liabilities | $0.88 million | $6.68 million |
| Stockholders’ equity | $17.66 million | $20.32 million |
There is no meaningful revenue margin to report. Capital expenditures were approximately $242,000, and cash declined by $8.02 million during the year. The company reported no debentures payable at June 30, 2018; current liabilities included a $298,000 warrant derivative liability. The accumulated deficit was $83.69 million. A gross deferred tax asset of $37.09 million was fully offset by a valuation allowance.
Material changes versus fiscal 2017
- Net loss narrowed by $1.74 million, while operating expenses declined by $276,000. R&D fell $705,000, which management attributed mainly to lower stock compensation and reduced staffing and supplies; G&A rose $429,000, including costs related to the former CEO’s departure and higher professional fees.
- Other income/expense included a $2.55 million gain from changes in derivative fair value, partly offset by a $1.35 million loss on extinguishment of debt. Lower interest and debt-discount expense also contributed to the smaller net loss; the result was not driven by revenue growth.
- The $5 million Series C debenture and related interest were redeemed through issuance of 5.5 million common shares; 150,000 Series A preferred shares were issued in connection with waiver of early-redemption payments. Common shares outstanding increased to 69.17 million from 63.31 million.
- Cash fell by approximately $8.02 million, and working capital declined by $4.18 million.
Outlook, risks, and unusual items
- Development plans: Management planned to select a shingles clinical candidate, produce material for IND-enabling toxicology studies, seek FDA pre-IND guidance, and work toward an IND and Phase I trial. At June 30, 2018, the candidate remained preclinical and no IND had been filed. The company reported that GMP-like production work began in September 2018, after the reporting period.
- Licensing dependency: NanoViricides did not yet hold a TheraCour license for VZV, its stated lead indication. Negotiations were active after year-end; there is no assurance an agreement would be reached or on favorable terms. TheraCour is a related party controlled primarily by the company’s president, and it received $3.18 million for development and other costs in FY 2018.
- Funding and going concern: The auditor’s report and company disclosures raise substantial doubt about the company’s ability to continue as a going concern. Management estimated available resources and contemplated financing could support operations through October 2019, but stated additional capital would be needed for clinical trials and further development. The company estimated about $9 million for the next 12 months and approximately $21 million for a subsequent two-year development period; these are management estimates, not committed funding. Potential financing was not subject to definitive agreements in the filing.
- Scientific and regulatory risk: Reported efficacy and safety findings are preclinical, including non-GLP safety work and human skin-patch organ-culture studies; they do not establish clinical safety or efficacy. Timelines and cost estimates are uncertain, and clinical trials, FDA review, manufacturing readiness, staffing, and reliance on outside collaborators could delay development. Management cautioned it could not reliably project approval timing.
- Financial reporting and listing: Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end, citing material weaknesses in review of filings, third-party valuation models, and income-tax accounting. The NYSE American had also notified the company of audit-committee composition noncompliance after director departures; the issue remained unresolved in the filing’s subsequent-events discussion.
- Other items: The company reported no material pending legal proceedings. Its audited financial statements received an unqualified opinion, with a going-concern explanatory paragraph; the auditor did not audit internal-control effectiveness.
Important facts for investors to verify
- Current cash, actual monthly burn, and whether financing was secured to fund operations and clinical development beyond the management-estimated runway.
- Status and terms of the TheraCour VZV license, including related-party safeguards and the company’s continuing dependence on TheraCour.
- Whether a shingles candidate was finalized, toxicology studies were completed, an IND was filed, and the FDA authorized clinical testing.
- Whether preclinical findings are reproducible and translate into human safety and efficacy; distinguish company-reported research results from clinical evidence.
- Share dilution and potential overhang from outstanding warrants, preferred shares, and future equity financing; confirm subsequent share-count changes.
- Remediation of the reported internal-control material weaknesses and restoration of NYSE American audit-committee compliance.